Phase 2a clinical trial of AR 13503 in patients with neovascular age-related macular degeneration and DME (diabetic macular edema)
Latest Information Update: 15 Mar 2023
At a glance
- Drugs AR 13503 (Primary)
- Indications Diabetic macular oedema; Wet age-related macular degeneration
- Focus Therapeutic Use
- Sponsors Aerie Pharmaceuticals; Alcon
- 22 Nov 2022 According to an Alcon media release, Aerie Pharmaceuticals has been acquired by Alcon.
- 11 May 2020 New trial record
- 06 May 2020 According to an Aerie Pharmaceuticals media release, initiation of this trial is expected in the second half of 2020, with a readout expected in 2021.